日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

PM01183 与拓扑替康治疗铂类耐药/难治性晚期卵巢癌患者的 II 期随机研究

Poveda, A; Del Campo, J M; Ray-Coquard, I; Alexandre, J; Provansal, M; Guerra Alía, E M; Casado, A; Gonzalez-Martin, A; Fernández, C; Rodriguez, I; Soto, A; Kahatt, C; Fernández Teruel, C; Galmarini, C M; Pérez de la Haza, A; Bohan, P; Berton-Rigaud, D

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

曲贝替定在促纤维增生性小圆细胞肿瘤细胞中的作用机制

Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini C M, D'Incalci M, Gatta R

Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity

显性负突变体使野生型p53失活,从而使MCF-7细胞对微管蛋白结合剂的细胞毒性产生抗性。

Galmarini, C M; Falette, N; Tabone, E; Levrat, C; Britten, R; Voorzanger-Rousselot, N; Roesch-Gateau, O; Vanier-Viornery, A; Puisieux, A; Dumontet, C